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ABSTRACT
Overwhelming evidence indicates that long non-coding RNAs have essential 
roles in tumorigenesis. Nevertheless, their role in the molecular pathogenesis of 
pediatric B-cell precursor acute lymphoblastic leukemia has not been extensively 
explored. Here, we conducted a comprehensive analysis of the long non-coding RNA 
transcriptome in ETV6/RUNX1-positive BCP-ALL, one of the most frequent subtypes 
of pediatric leukemia. First, we used primary leukemia patient samples to identify an 
ETV6/RUNX1 specific expression signature consisting of 596 lncRNA transcripts. Next, 
integration of this lncRNA signature with RNA sequencing of BCP-ALL cell lines and 
lncRNA profiling of an in vitro model system of ETV6/RUNX1 knockdown, revealed 
that lnc-NKX2-3-1, lnc-TIMM21-5, lnc-ASTN1-1 and lnc-RTN4R-1 are truly regulated 
by the oncogenic fusion protein. Moreover, sustained inactivation of lnc-RTN4R-1 
and lnc-NKX2-3-1 in ETV6/RUNX1 positive cells caused profound changes in gene 
expression. All together, our study defined a unique lncRNA expression signature 
associated with ETV6/RUNX1-positive BCP-ALL and identified lnc-RTN4R-1 and lnc-
NKX2-3-1 as lncRNAs that might be functionally implicated in the biology of this 
prevalent subtype of human leukemia.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) is an 
aggressive hematological malignancy that results 
from the accumulation of genetic alterations in B- or 
T-lymphoid precursor cells [1–3]. Approximately 25% 
of pediatric B-cell precursor ALL (BCP-ALL) patients 
carry the t(12;21)(p13;q22) translocation, which fuses 
the N-terminal part of the ETS variant 6 (ETV6) with 
virtually the entire Runt-related transcription factor 1 
(RUNX1). Although most ETV6/RUNX1-positive BCP-
ALL patients have an excellent prognosis with current 
treatment protocols, some patients still experience a late 
disease relapse [4, 5].
Ample evidence, including the detection of ETV6/
RUNX1 fusion transcripts in neonatal blood spots as well 
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as the development of concordant B-ALL in monozygotic 
twins, has suggested that t(12;21)(p13;q22) translocation 
can originate in utero [6]. Nevertheless, several additional 
genetic alterations are supposed to accumulate in ETV6/
RUNX1-positive pre-leukemic hematopoietic cells in order 
to trigger full malignant transformation [7].
Previous reports have shown that the ETV6/RUNX1 
fusion protein leads to expansion of B-cell precursors with 
enhanced self-renewal capacity and impaired differentiation 
[8–13]. In addition, several mechanisms of action have been 
proposed for this chimeric protein, including repression of 
normal RUNX1 target genes, disruption of wild type ETV6 
transcriptional activity and re-localization of transcriptional 
cofactors from the nucleus into the cytoplasm [14–16]. 
Finally, genome-wide profiling studies have shown that 
ETV6/RUNX1-positive leukemias are characterized by 
a unique gene expression signature as compared to other 
genetic subtypes of human BCP-ALL with differential 
expression of genes involved in differentiation, apoptosis, 
signal transduction and immune response [17–19].
Recently, it became clear that a significant portion of 
the human genome consists of non-coding transcripts such as 
tRNAs, snoRNAs, microRNAs and long non-coding RNAs 
(lncRNAs). Although only a fraction of lncRNAs have been 
functionally characterized, increasing evidence shows that 
these long non-coding transcripts can play important roles 
in different cellular processes, including regulation of gene 
expression, guidance of chromatin remodeling complexes, 
X-chromosome inactivation, genomic imprinting, nuclear 
compartmentalization, nuclear cytoplasmic trafficking, RNA 
splicing and translational control. Moreover, besides their 
putative roles in normal development, lncRNAs have also 
been implicated in a variety of human diseases, including 
cancer [20–23]. Sporadic examples of lncRNAs involved 
in the pathogenesis of BCP-ALL have been reported. For 
example, overexpression of lncRNA BALR-2 correlated 
with poor clinical outcome and a reduced prednisone 
response in human BCP-ALLs [24]. Furthermore, another 
study identified a unique lncRNA expression signature in 
MLL-rearranged ALLs, which could be exploited for the 
identification of novel biomarkers for this disease [25]. 
Nevertheless, the full spectrum of lncRNA expression 
patterns in BCP-ALL remains largely unexplored.
Here, we provide a comprehensive overview of 
lncRNA expression in ETV6/RUNX1-positive BCP-ALL 
and analyze the transcriptional consequences of lncRNA 
modulation in the context of ETV6/RUNX1 rearranged 
leukemia.
RESULTS
LncRNA expression in ETV6/RUNX1-driven 
BCP-ALL
To study the role of lncRNAs in the molecular 
pathogenesis of human BCP-ALL, we profiled a cohort of 
64 primary BCP-ALL patient samples using a previously 
published microarray platform that simultaneously detects 
lncRNA and mRNA transcripts [26]. This patient cohort 
consisted of 25 ETV6/RUNX1-positive, 7 TCF3/PBX1-
positive, 15 high hyperdiploid and 17 normal karyotype 
BCP-ALLs. Using 14055 probes that showed expression 
above the background, we established an ETV6/RUNX1-
specific lncRNA signature consisting of 596 lncRNA 
transcripts (434 up- and 162 down-regulated) that showed 
significant differential expression between ETV6/RUNX1-
positive BCP-ALL and other genetic BCP-ALL subclasses 
(adj. p-value<0.05, Figure 1A, Supplementary Table S1). 
In our dataset, average lncRNA expression was lower as 
compared to mRNA transcripts (Figure 1B), a notion that 
has previously been reported in other studies [27].
Identification of ETV6/RUNX1 specific lncRNAs 
by RNA sequencing of human BCP-ALL cell 
lines
To further validate our initial findings and to 
evaluate the ETV6/RUNX1-positive BCP-ALL cell line 
REH, as a suitable in vitro model system to study the 
functional relevance of ETV6/RUNX1-specific lncRNAs, 
we analyzed publically available non-stranded poly-A 
RNA sequencing data from 13 human BCP-ALL tumor 
lines including REH and 12 other non-ETV6/RUNX1 cell 
lines (SEM, SUP-B15, NALM-6, NALM-19, RCH-ACV, 
RS4;11, KASUMI-2, KOPN-8, MUTZ-5, MHH-CALL-2, 
MHH-CALL-3 and MHH-CALL-4).
More specifically, using differential expression 
analysis of sequence count data (DESeq2 [28]), we 
identified 50 lncRNAs that showed a significant 
differential expression between REH and the other non-
ETV6/RUNX1 cell lines (Generalized Linear Model; adj. 
p-value <0.05), including 28 up- and 22 down-regulated 
lncRNA transcripts (Figure 1C; Supplementary Table S2). 
Interestingly, 16 out of 50 lncRNAs overlapped with 
the ETV6/RUNX1-specific lncRNA signature that was 
identified in the primary leukemia samples, including 14 
up- and 2 down-regulated lncRNA transcripts (Figure 1C; 
Supplementary Table S3).
Next, we performed chromatin immunoprecipitation 
followed by sequencing (ChIP-seq) to evaluate the 
genome-wide distribution of H3K27 acetylation 
(H3K27ac), a histone mark indicative for active promoters 
and/or putative enhancer regions, in an ETV6/RUNX1-
positive (REH) and negative (697) BCP-ALL cell line. 
Notably, differential H3K27ac binding between REH and 
697 cells was identified at the respective genomic loci of 
12 out of 16 ETV6/RUNX1 associated lncRNAs identified 
above (Supplementary Figure S1). As a representative 
example, sequencing tracks for lnc-LRP8-3 are shown 
in Figure 1D. In general, broad H3K27ac binding, 
covering the whole lncRNA transcript, was identified in 
the REH cell line for lnc-NKX2-3-1, lnc-RTN4R-1, lnc-
GIP-1, lnc-LRP8-3, lnc-TCF12-2, lnc-C8orf4-1, lnc-
C8orf4-2, lnc-TINAGL1-1 and lnc-LSM11-4, whereas 
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Figure 1: Specific lncRNA expression pattern in ETV6/RUNX1-driven BCP-ALL. A. MA-plots, which display the mean 
expression and fold change of differentially expressed lncRNAs in ETV6/RUNX1 driven leukemias (adjusted p-value < 0.05) identified by 
microarray expression profiling B. Density plot of average normalized expression values for lncRNAs and mRNA transcripts in 25 ETV6/
RUNX1-positive BCP-ALLs C. Diagonal plot that represents differentially up-regulated (Red) and down-regulated (Blue) lncRNAs in an 
ETV6/RUNX1-positive BCP-ALL cell line identified by RNA-sequencing of 13 BCP-ALL cell lines (adjusted p-value < 0.05). D. RNA 
sequencing tracks that represent expression of lnc-LRP8-3 in five BCP-ALL cell lines and H3K27ac binding patterns (ChIP-Seq) of the 
same genomic locus in REH and 697 cells.
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more discrete H3K27ac peaks were identified at putative 
promoter regions for lnc-TIMM21-5 and lnc-CPT2-7 
(Supplementary Figure S1).
Identification of ETV6/RUNX1 regulated 
lncRNAs
To further confirm the association between ETV6/
RUNX1 and lncRNA expression signatures, we silenced 
the fusion protein in REH cells using a short hairpin 
RNA (shRNA) targeting the ETV6 moiety of the fusion 
transcript (Figure 2A). Given that REH cells harbor 
an ETV6/RUNX1 translocation with a concomitant 
deletion of the remaining wildtype ETV6 allele, this 
shRNA will exclusively modulate the expression of the 
fusion transcript. Next, we used the same microarray 
platform [26] for lncRNA profiling and identified 134 
lncRNAs that showed differential expression between 
biological triplicates of ETV6/RUNX1 knockdown and 
the corresponding REH control samples (41 lncRNAs 
up- and 93 down-regulated; adj. p-value<0.05; Figure 2B; 
Supplementary Table S4).
Among the lncRNAs that were significantly affected 
by ETV6/RUNX1 modulation, only four transcripts 
(lnc-NKX2-3-1, lnc-TIMM21-5, lnc-ASTN1-1 and lnc-
RTN4R-1) overlapped with the 16 ETV6/RUNX1 
associated lncRNAs identified above (Figure 2B). The 
specific expression pattern of these four lncRNAs in 
ETV6/RUNX1-positive leukemia patients as well as 
their H3K27ac binding patterns (ChIP-Seq) and RNA 
sequencing tracks in REH and 697 cells are visualized in 
Supplementary Figure S2 and Figure 2C, respectively.
To investigate potential functionalities for each 
of these four ETV6/RUNX1 regulated lncRNAs, we 
performed in silico guilt-by-association analysis using the 
lncRNA and mRNA expression profiles of 64 BCP-ALL 
patients. Considering that the output of this analysis is 
based on the correlation between the lncRNA-of-interest 
and all protein coding genes and the fact that these 
lncRNAs are ETV6/RUNX1-specific, performing this 
analysis in the whole cohort of patients was influenced by 
the subgroup bias and resulted in the same functionalities 
for all four lncRNAs. To remove this subgroup bias, 
we performed this analysis exclusively in 25 ETV6/
RUNX1-positive BCP-ALL patients. Notably, this 
approach suggested that lnc-NKX2-3-1, lnc-TIMM21-5, 
lnc-ASTN1-1 and lnc-RTN4R-1 have both unique as 
well as overlapping functionalities. For example, mRNA 
processing, processing of capped intron-containing pre-
mRNA, mRNA splicing and resistance to vincristine, 
were amongst the top 30 most correlated gene sets for all 
four lncRNAs mentioned above (Figure 3). Nevertheless, 
each lncRNA also showed unique patterns of positive and 
negative correlations at the single gene level, as shown by 
the top 10 most correlated transcripts for each lncRNA in 
Supplementary Figure S3.
Given the predicted link between these lncRNAs 
and resistance to vincristine, we examined whether these 
lncRNAs are able to identify a more aggressive subtype of 
ETV6/RUNX1-derived leukemia. We were able to compare 
the levels of lncRNA expression between relapsed (n=3) 
and non-relapsed (n=22) samples at time of diagnosis. 
Notably, this analysis revealed that the average expression 
levels of lnc-TIMM21-5 and lnc-RTN4R-1 are significantly 
higher in the diagnostic samples of the three cases that 
experienced relapse, as compared to the 22 ETV6/RUNX1-
positive BCP-ALLs in complete remission (logFC=1.1; 
Supplementary Table S5). Moreover, we were able to 
collect paired samples from a new ETV6/RUNX1-positive 
ALL patient (not included in the initial 25 ETV6/RUNX1-
positive cases), for which leukemic cells were available 
at the time of initial diagnosis as well as at relapse. 
Comparison of the expression levels of the four lncRNAs 
between diagnosis and relapse revealed upregulation 
of lnc-NKX2-3-1, lnc-RTN4R-1 and lnc-TIMM21-5 at 
the time of relapse, whereas lnc-ASTN1-1 displayed an 
opposite behavior (Supplementary Figure S4).
LncRNA modulation in ETV6/RUNX1-positive 
BCP-ALL cell lines
To further study the biological functions of lnc-
NKX2-3, lnc-TIMM21, lnc-ASTN1 and lnc-RTN4R in the 
context of ETV6/RUNX1-driven leukemogenesis, we 
used LNA GapmeR technology to evaluate transcriptional 
effects of lncRNA modulation in vitro. For each lncRNA, 
we evaluated the capacity of eight different LNA 
GapmeRs to silence lncRNA expression levels in REH 
cells through gymnosis [29]. Using this passive uptake 
approach, we identified two independent LNA GapmeRs 
for each lncRNA that showed at least 80% lncRNA 
knockdown, as evaluated by RT-qPCR (Figure 4A).
To evaluate the transcriptional consequences 
of these lncRNA perturbations, we performed RNA 
sequencing and profiled biological triplicates of two 
independent LNA GapmeR knockdown experiments 
for each lncRNA together with their respective control 
samples in the REH cell line (6 versus 6 for each lncRNA). 
Strikingly, modulation of lnc-TIMM21-5 and lnc-ASTN1-1 
caused no or very limited effects on overall transcription 
in REH cells (Supplementary Figure S5). However and 
most notably, gene transcription was severely affected 
by perturbations of lnc-NKX2-3-1 and lnc-RTN4R-1 
(Figure 4B).
More specifically, lnc-NKX2-3-1 inactivation 
resulted in significant changes in the expression of 
75 transcripts (43 up- and 32 down-regulated; adj. 
p-value<0.05; Figure 4B; Supplementary Table S6). 
Of note, different immunoglobulin heavy and lambda 
transcripts (IGHV3-15, IGLV2-23, IGLV3-10, IGLV3-
21, IGLC3, IGLC6 and IGLC7) were amongst the most 
significantly up-regulated genes after lnc-NKX2-3-1 
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modulation (Supplementary Table S6). Moreover, 
functional annotations of up- and down-regulated genes 
upon lnc-NKX2-3-1 knockdown in REH cells revealed 
that this lncRNA mainly impacts transcriptional regulation 
(Supplementary Figure S6).
Interestingly, expression changes were even more 
pronounced upon lnc-RTN4R-1 knockdown in REH cells, 
with significant changes for 367 transcripts (241 up- 
and 126 down-regulated; adj. p-value<0.05; Figure 4B; 
Supplementary Table S7). Of note, 23 out of the 126 
down-regulated genes showed correlation (r>0.5) with lnc-
RTN4R-1 in the guilt-by-association analysis, which was 
performed on ETV6/RUNX1-positive patients samples. 
These data further confirm the positive regulatory role of 
lnc-RTN4R-1 at transcriptional level. Moreover, functional 
annotation of genes down-regulated after lnc-RTN4R-1 
knockdown in REH cells revealed significant enrichment 
of genes involved in transcriptional regulation and anti-
Figure 2: Identification of ETV6/RUNX1 regulated lncRNA. A. Western blot (top) and RT-qPCR (below) analysis of ETV6/
RUNX1 protein and transcript in REH cells upon fusion knockdown (KD). RCH-ACV used as an ETV6/RUNX1-negative B-ALL cell line 
with wild type ETV6. This result is representative for three independent biological replicates. B. Volcano plot representing the differentially 
expressed lncRNAs (red) when comparing fusion knockdown to the scramble (adjusted p-value < 0.05). C. RNA sequencing tracks (RNA-
Seq) and H3K27ac binding patterns (ChIP-Seq) for lnc-NKX2-3-1, lnc-TIMM21-5, lnc-ASTN1-1 and lnc-RTN4R-1 in REH and 697 cell 
lines.
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apoptosis (Figure 4C). In contrast, up-regulated genes 
upon lnc-RTN4R-1 knockdown were enriched in kinase 
signalling and apoptosis (Figure 4C).
Finally, we evaluated to what extent the genes 
affected by lnc-RTN4R-1 perturbation could also be 
recapitulated in the ETV6/RUNX1 specific mRNA 
expression profile in primary patient samples and/or 
the ETV6/RUNX1 knockdown signature in REH cells. 
Notably, GSEA analysis revealed significant enrichment 
of genes down regulated upon lnc-RTN4R-1 knockdown 
in transcripts that are highly expressed in ETV6/RUNX1-
positive BCP-ALL, suggesting that lnc-RTN4R-1 indeed 
plays a role in the establishment of part of the ETV6/
RUNX1-specific gene expression signature (Figure 
5A). More specifically, from the 126 transcripts that 
are significantly down regulated upon lnc-RTN4R-1 
knockdown in REH cells, nine were significantly up 
regulated in ETV6/RUNX1-positive BCP-ALLs. The 
leading edge of this analysis included AK7, PTPRK and 
GBA3, which are the most prominent examples of genes 
that are significantly down-regulated after lnc-RTN4R-1 
knockdown, highly expressed in ETV6/RUNX1-positive 
BCP-ALL and also significantly down-regulated after 
fusion protein knockdown (Figure 5A–5B).
DISCUSSION
Emerging evidence suggests that lncRNAs are 
critically involved in a variety of human tumor entities 
[20–23] and the identification of cancer-associated 
lncRNAs might reveal new prognostic biomarkers or 
novel therapeutic strategies for the treatment of human 
cancer. In this study, we characterized the lncRNA 
expression signature associated with ETV6/RUNX1-
positive BCP-ALL, one of the most prevalent genetic 
subtypes of childhood leukemia.
A previous study by Fernando and colleagues [24] 
also evaluated lncRNA expression signatures in genetic 
subtypes of human BCP-ALL using 14 ETV6/RUNX1, 
15 TCF3/PBX1 and 15 MLL-rearranged leukemia 
specimens. Although their study was not only focused on 
the identification of subtype specific lncRNA signatures, 
the ETV6/RUNX1 specific expression of lnc-BTBD10-3 
(LINC00958) reported in their study, could be confirmed 
in our dataset.
However, besides using primary BCP-ALL patient 
samples, we also integrated these lncRNA expression 
data with RNA sequencing results from a panel of human 
BCP-ALL leukemia cell lines and identified a unique 
lncRNA expression profile of 16 lncRNAs exclusively 
associated with the presence of the ETV6/RUNX1 fusion 
protein. Notably, lnc-SARDH-1 (also known as DBH-
AS1) was the only lncRNA from this list for which an 
oncogenic role has previously been postulated. Indeed, 
DBH-AS1 promotes cell proliferation and cell survival 
through activation of MAPK signaling in the context of 
hepatocellular carcinoma [30].
Given that previous studies revealed putative 
overlap between lncRNA expression and regulatory 
enhancer elements [31–33], we also evaluated the 
distribution of H3K27ac, a histone modification associated 
with enhancer activity, at the genomic loci of the 16 ETV6/
Figure 3: Attributing functional annotation to ETV6/RUNX1 specific lncRNAs through guilt-by-association analysis. 
Selection of top enriched gene sets correlated with the expression of lnc-NKX2-3-1, lnc-TIMM21-5, lnc-ASTN1-1 and lnc-RTN4R-1 in 25 
ETV6/RUNX1-positive BCP-ALL patients. FDR stands for false discovery rate.
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Figure 4: Transcriptional consequences of lncRNA modulation in the context of ETV6/RUNX1 rearranged leukemia 
cases. A. RT-qPCR analysis of lncRNA knockdown experiments using two independent LNA GapmeRs for each lncRNA. This plot is 
representative for three independent biological replicates and knockdown was evaluated with three different primer pairs for each lncRNA. 
B. MA-plots, which display the mean expression and fold change of RNA sequencing data of REH cells upon lnc-NKX2-3-1 and lnc-
RTN4R-1 knockdown. Significantly differentially expressed genes are represented in red. C. Functional annotation of genes down- and 
up-regulated upon lnc-RTN4R-1 knockdown in REH cell line.
Oncotarget73776www.impactjournals.com/oncotarget
RUNX1 specific lncRNAs mentioned above. Notably, 
broad H3K27ac binding was identified for lnc-NKX2-3-1, 
lnc-RTN4R-1, lnc-GIP-1, lnc-LRP8-3, lnc-TCF12-2, lnc-
C8orf4-1, lnc-C8orf4-2, lnc-TINAGL1-1 and lnc-LSM11-4 
in ETV6/RUNX1-positive REH cells. Interestingly, coding 
genes adjacent to some of these lncRNAs showed unique 
overexpression in ETV6/RUNX1-positive BCP-ALLs, 
suggesting a possible cis regulatory relationship between 
these lncRNAs and their nearby protein coding genes. 
For example, the RNA-binding protein IGF2BP1, which 
is one of the most significantly up-regulated mRNA 
transcripts in ETV6/RUNX1-positive BCP-ALL and acts 
as a potent regulator of ETV6/RUNX1 mRNA stability 
[34], is located antisense of lnc-GIP-1 with an overlap at 
their respective first exons. Therefore, lnc-GIP-1 could be 
directly involved in the regulation of IGF2BP1 expression 
in the pathogenesis of BCP-ALL. Notably, IGF2BP1 
has recently been reported as a novel IGH translocation 
partner in BCP-ALL [35]. Furthermore, we also identified 
a strong correlation in ETV6/RUNX1-positive leukemias 
between NETO1 and its adjacent, bidirectional lncRNA 
lnc-TIMM21-5 (r = 0.89) as well as between LRP8 and 
lnc-CPT2-7 (r = 0.70). Of note, lnc-TIMM21-5 and 
lnc-CPT2-7 showed discrete H3K27ac peaks at their 
respective promoter sites, instead of broad H3K27ac 
binding as was observed for some of the other lncRNAs. 
It will be of interest to investigate whether these lncRNAs 
truly participate in the local gene regulation. However, a 
recent study showed that correlation between expression 
of a lncRNA and its neighboring protein coding gene 
might be due to the processes of lncRNA’s transcription 
or splicing which increase local concentration of 
transcription-associated factors at the promoter loci of 
adjacent protein coding gene regardless of the lncRNA 
sequence [36].
Finally, we applied shRNA-mediated silencing of 
endogenous ETV6/RUNX1 to narrow down the list of 
the lncRNAs are truly regulated by the oncogenic fusion 
protein to lnc-NKX2-3-1, lnc-TIMM21-5, lnc-ASTN1-1 
and lnc-RTN4R-1. Interestingly, subsequent lncRNA 
modulation experiments using LNA GapmeR technology 
revealed that lnc-TIMM21-5 and lnc-ASTN1-1 modulation 
Figure 5: Integration of transcriptional consequences of lncRTN4R-1 modulation with ETV6/RUNX1 specific mRNA 
signatures in primary B-ALLs and REH cells. GSEA shows that the 126 genes that are significantly down-regulated upon lnc-
RTN4R-1 knockdown are significantly enriched in both ETV6/RUNX1-positive BCP-ALL patient samples A. as well as in genes that are 
down-regulated upon ETV6/RUNX1 knockdown in REH cells B.
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has no effect on overall transcription, suggesting that 
these lncRNAs might act at the translational level, as 
has been described for other lncRNAs, including the 
PU.1 antisense lncRNA [37] or/and at various processing 
steps of pre-mRNA. In contrast, lnc-NKX2-3-1 and lnc-
RTN4R-1 perturbations resulted in severe changes in 
gene expression, suggesting an alternative mechanism of 
action for these lncRNAs that is more transcriptionally 
oriented. Most notably, loss of lnc-RTN4R-1 expression 
significantly affected part of the ETV6/RUNX1-specific 
mRNA expression signature as exemplified by reduced 
levels of AK7, PTPRK and GBA3. All together, our study 
identified a panel of ETV6/RUNX1-specific lncRNAs 
that might be implicated in the biology of human BCP-
ALL and could serve as novel therapeutic target for this 
prevalent subtype of human leukemia.
MATERIALS AND METHODS
Clinical samples
Diagnostic bone marrow samples of 64 children with 
BCP-ALL, enrolled in subsequent trials of the European 
Organization for Research and Treatment of Cancer, 
Childhood Leukemia Group (EORTC-CLG) between July 
1998 to July 2012, were acquired after obtaining informed 
consent from patients or their legal guardians according 
to the declaration of Helsinki. This cohort consisted of 25 
cases with t(12;21)(p13;q22) [ETV6/RUNX1], seven cases 
with t(1;19)(q23;p13) [TCF3/PBX1], 15 high hyperdiploid 
BCP-ALLs (>50 chromosomes) and 17 BCP-ALLs with 
a normal karyotype (absence of any numerical aberrations 
or translocations). Moreover, bone marrow samples at the 
time of initial diagnosis (1998-2012) as well as at relapse 
(2015) were acquired from a new ETV6/RUNX1 patient, 
which was not included in the initial 25 ETV6/RUNX1 
cases. High-quality RNA from the bone marrow samples 
was isolated and was used for microarray based expression 
profiling.
Cell culture
BCP-ALL cell lines (REH, RCH-ACV, 697) were 
obtained from the DSMZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH) repository. 
Cells were cultured in RPMI 1640 media (Life 
Technologies Europe) supplemented with 10% fetal 
bovine serum (Biochrom AG), 1% penicillin/streptomycin 
(Life Technologies Europe), 1% kanamycin (Life 
Technologies Europe), 1% glutamine (Life Technologies 
Europe) at 37° C in 5% CO2.
RNA isolation, cDNA synthesis and RT-qPCR
Total RNA was isolated using the miRNeasy mini 
or micro kit (Qiagen) according to the manufacturer's 
instructions. For each sample, RNA quality and purity 
were assessed by Experion analysis (Bio-Rad, Nazareth 
Eke, Belgium) and concentration was measured using 
the NanoDrop ND-1000 (NanoDrop Technologies, 
Wilmington, DE, USA). cDNA was generated using 
the iScript cDNA synthesis kit (Bio-Rad, Nazareth Eke, 
Belgium) according to the instructions of the manufacturer. 
After cDNA preparation, reverse transcription quantitative 
real-time polymerase chain reaction (RT-qPCR) was 
carried out using custom 2X SsoAdvanced SYBR Green 
Supermix (Bio-Rad) in two technical replicates. Briefly, 2 
μl cDNA (2.5 ng/μL) was added to 3 μl of PCR mix (2.5 
μl 2X SsoAdvanced mastermix, 0.25 μl Forward Primer 
(5μM), 0.25 μl Reverse Primer (5μM)). qRT-PCR was 
performed on a LightCycler 480 (Roche) and data were 
analyzed using qBasePLUS software (Biogazelle) [38]. 
Relative expression values were calculated using the ΔCt-
method. For normalization, the expression of at least three 
reference genes was combined to calculate a normalization 
factor. The primer sequences are listed in Supplementary 
Table S8.
Western blotting
Total protein isolation was performed using RIPA-
lysis buffer, supplemented with protease inhibitors and 
SDS-PAGE was executed according to standard protocols. 
Blotting was performed on a PVDF Membrane and the 
membrane blocked with 5% milk. For immunoblotting, 
the mouse monoclonal antibody against ETV6 (Abnova, 
H00002120-M01) was used in a 1:1000 dilution and the 
mouse monoclonal antibody against actin (Sigma, A2228) 
in a 1:5000 dilution. The anti-mouse secondary antibodies 
were used in a 1:5000 dilution.
Microarray profiling
RNA samples were profiled on a custom designed 
Agilent micro-array covering all protein coding genes 
and 23042 lncRNAs as described by Volders et al. [26]. 
A total of 100 ng input RNA was used to complete the 
profiling according to the manufacturer’s protocol (One-
color Microarray-Based Gene Expression Analysis, 
Low Input Quick Amp Labeling, Agilent Technologies). 
Normalization of the expression data was performed 
using the VSN-package (BioConductor release 2.12) in R 
bioconductor. Expression values were further subjected to 
background subtraction and probes detecting a 10% higher 
expression as compared to the negative controls in at least 
60% of one genetic subtype of BCP-ALL, were retained 
for further analysis. Following the normalization of gene-
expression microarray data and background correction, 
differentially expressed genes between ETV6/RUNX1-
positive BCP-ALLs and other subgroups were determined 
using the limma in the R bioconductor. All p-values were 
corrected for multiple testing using the ‘‘Benjamini-
Hochberg’’ correction method (p<0.05). Data were 
submitted to Gene Expression Omnibus (GSE79873).
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RNA-seq analysis
Publically available RNA sequencing data were 
obtained from the Cancer Cell Line Encyclopedia for a 
panel of 13 human BCP-ALL cell lines including one 
ETV6/RUNX1-positive (REH) and 12 ETV6/RUNX1-
negative (SEM, SUP-B15, NALM-6, NALM-19, RCH-
ACV, RS4;11, KASUMI-2, KOPN-8, MUTZ-5, MHH-
CALL-2, MHH-CALL-3, MHH-CALL-4) human 
BCP-ALL cell lines.
Total RNA was extracted from REH and 697 cells, 
as well as from REH cells treated with LNA gapmeRs 
against four different lncRNAs and a non-targeting 
gapmeR using the miRNeasy mini kit (Qiagen) according 
to the manufacturer's instructions. The RNA quality was 
evaluated using a RNA Nano chip on a Bioanalyzer 
(Agilent technologies). For library preparation, the 
Illumina TruSeq RNA sample Prep Kit (San Diego, CA, 
USA) was used according to the manufacturer’s protocol. 
Library quality was checked using a DNA-1000 chip on 
a Bioanalyzer (Agilent technologies). Briefly, 100 ng of 
total RNA was poly-A purified, fragmented and first-strand 
cDNA reverse transcribed using the Truseq protocol. Next, 
second-strand cDNA synthesis, end repair, addition of a 
single A base, adaptor ligation and PCR amplification was 
performed and enriched cDNA libraries were sequenced 
using an Illumina NextSeq 500 sequencer instrument. 
RNA sequencing data have been deposited to the GEO 
repository (GSE79873). Reads were aligned to the 
reference genome hg38 with STAR-2.4.2a and differential 
expression analysis was performed using DESeq2 [28].
Lentiviral short hairpin RNA knockdown of the 
ETV6/RUNX1 fusion
Two ETV6 short hairpin (sh) (TRCN0000003854, 
TRCN0000003855) were purchased from Sigma-Aldrich 
and the green fluorescent protein (GFP) gene was inserted 
in the backbone of these vectors. Only one of these 
ETV6 specific shRNAs targeted the ETV6/RUNX1 
fusion transcript, whereas the other was used as a non-
targeting control. These plasmids were co-transfected 
with packaging and envelope vectors in HEK293TN 
cells using jet-PEI (VWR). 48h following transfection, 
viral supernatants were collected and REH cells were 
transduced in the presence of 8 μg/mL polybrene by 
spinoculation at 2300 rpm, 32°C for 90 minutes. After 72 
hours, GFP-positive cells were sorted using the Bio-Rad 
S3e Cell Sorter device.
LNA treatment of BCP-ALL cell lines
REH cells were seeded in 48-well plates (260μl, 
300,000 cells/well) and transfected with LNA™ (locked 
nucleic acid) GapmeRs (Exiqon) by gymnosis (passive 
uptake) to obtain a final GapmeR concentration of 10μM 
(Supplementary Table S9). Next, RNA isolation was 
carried out using miRNeasy micro kit (Qiagen) according 
to the manufacturer's instructions 72h after transfection. 
The biological triplicates for these experiments were 
executed on different days.
Chromatin immunoprecipitation (ChIP) 
sequencing
ChIP sequencing was performed as previously 
described [39] starting from 10*107 REH cells. Nuclei 
were isolated and chromatin was purified by chemical 
lysis and the purified chromatin was fragmented to 
200-300 bp fragments by sonication (Covaris, S220, 
Focused-ultrasonicator). Chromatin immunoprecipitation 
was performed by incubation of the chromatin fraction 
overnight with 100 μl of protein-A coated beads (Thermo-
Scientific) and 10 μg of fibrillarin-specific (Abcam, 
ab5821) or H3K27ac-specific antibodies (Abcam, 
ab4729). The next day, beads were washed to remove 
non-specific binding events and enriched chromatin 
fragments were eluted from the beads, followed by reverse 
cross-linking by incubation at 65°C overnight. DNA was 
subsequently purified by phenol/chloroform extraction 
and used for library preparation and sequencing using an 
Illumina Hiseq 2000 device (San Diego, CA, USA). Raw 
sequencing data were mapped to the human reference 
genome (GRCh37/h19) using Bowtie. Peak calling was 
performed using MACS 1.4. The ChIP-seq data were 
deposited in the GEO database (GSE79873).
Guilt-by-association analysis
Spearman correlation coefficients were calculated 
between lncRNAs and all protein coding genes using 
expression data of BCP-ALLs profiled on the custom 
designed Agilent array. The correlation values of each 
lncRNA and all protein coding genes were subsequently 
ranked from the highest to the lowest value and used as 
input for pre-ranked gene set enrichment analysis (GSEA), 
using the c2v5.0 MsigDB collection as gene set database 
(http://www.broad.mit.edu/gsea/) [40].
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